{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:21:27Z","timestamp":1773660087671,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.tvjl.2022.105854","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T12:49:36Z","timestamp":1656593376000},"page":"105854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evaluation of PEG-L-asparaginase in asparagine suppression and anti-drug antibody development in healthy Beagle dogs: A multi-phase preclinical study"],"prefix":"10.1016","volume":"286","author":[{"given":"L.R.","family":"Feenstra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gehring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.M.","family":"van Geijlswijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.M.T.","family":"Prinsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Vandemeulebroecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lammens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Krupa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Teske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2022.105854_bib1","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: Results from Children's Oncology Group Study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.tvjl.2022.105854_bib2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","article-title":"Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future","volume":"44","author":"Avramis","year":"2005","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.tvjl.2022.105854_bib3","first-page":"176","article-title":"Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012","volume":"57","author":"Blake","year":"2016","journal-title":"The Canadian Veterinary Journal"},{"key":"10.1016\/j.tvjl.2022.105854_bib4","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32","author":"Boos","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.tvjl.2022.105854_bib5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00280-014-2506-9","article-title":"Comparative pharmacokinetic\/pharmacodynamic characterisation of a new pegylated recombinant E. coli-L-asparaginase preparation (MC0609) in Beagle dog","volume":"74","author":"Borghorst","year":"2014","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.tvjl.2022.105854_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-74-6-893","article-title":"L-asparaginase: Clinical, biochemical, pharmacological, and immunological studies","volume":"74","author":"Capizzi","year":"1971","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.tvjl.2022.105854_bib7","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/jvim.15723","article-title":"Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs","volume":"34","author":"Cawley","year":"2020","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2022.105854_bib8","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood-2013-10-535112","article-title":"The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells","volume":"123","author":"Chan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tvjl.2022.105854_bib9","series-title":"Comparative Pharmacokinetics: Principles, Techniques and Applications","first-page":"295","article-title":"Study design and data analysis","author":"Chittenden","year":"2011"},{"key":"10.1016\/j.tvjl.2022.105854_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpb.2020.04.026","article-title":"Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice","volume":"152","author":"Elsadek","year":"2020","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.tvjl.2022.105854_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s40883-021-00198-y","article-title":"Clinical relevance of pre-existing and treatment-induced anti-poly(ethylene glycol) antibodies","volume":"8","author":"Freire Haddad","year":"2022","journal-title":"Regenerative Engineering and Translational Medicine"},{"key":"10.1016\/j.tvjl.2022.105854_bib12","first-page":"256","article-title":"The effects of immunization to L-asparaginase on antitumor and enzymatic activity","volume":"33","author":"Goldberg","year":"1973","journal-title":"Cancer Research"},{"key":"10.1016\/j.tvjl.2022.105854_bib13","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jama.1967.03130220070012","article-title":"L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia","volume":"202","author":"Hill","year":"1967","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.tvjl.2022.105854_bib14","first-page":"466","article-title":"L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow","volume":"30","author":"Ho","year":"1970","journal-title":"Cancer Research"},{"key":"10.1016\/j.tvjl.2022.105854_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5326\/0410221","article-title":"Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma","volume":"41","author":"Jeffreys","year":"2005","journal-title":"Journal of the American Animal Hospital Association"},{"key":"10.1016\/j.tvjl.2022.105854_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.mph.0000166919.29879.2c","article-title":"L-asparaginase: Old dog, more tricks and leukemia: not simply a liquid tumor","volume":"27","author":"Kamen","year":"2005","journal-title":"Journal of Pediatric Hematology Oncology"},{"key":"10.1016\/j.tvjl.2022.105854_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/vco.12014","article-title":"Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase","volume":"13","author":"Kidd","year":"2015","journal-title":"Veterinary and Comparative Oncology"},{"key":"10.1016\/j.tvjl.2022.105854_bib18","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1939-1676.2005.tb02753.x","article-title":"Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?","volume":"19","author":"MacDonald","year":"2005","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2022.105854_bib19","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/1097-0142(19870615)59:12<2011::AID-CNCR2820591207>3.0.CO;2-M","article-title":"A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma","volume":"59","author":"MacEwen","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.tvjl.2022.105854_bib20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1939-1676.1992.tb00344.x","article-title":"Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy: a randomized double-blind study in canine lymphoma","volume":"6","author":"MacEwen","year":"1992","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2022.105854_bib21","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.tvjl.2022.105854_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.16495","article-title":"Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium","volume":"190","author":"Mondelaers","year":"2020","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.tvjl.2022.105854_bib23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/vco.12749","article-title":"Efficacy and adverse events of continuous l-asparaginase administration for canine large cell lymphoma of presumed gastrointestinal origin","volume":"20","author":"Nakagawa","year":"2022","journal-title":"Veterinary and Comparative Oncology"},{"key":"10.1016\/j.tvjl.2022.105854_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children\u2019s cancer group study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"Journal of Pediatric Hematology Oncology"},{"key":"10.1016\/j.tvjl.2022.105854_bib25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/01652176.1999.9694990","article-title":"Evaluation of the results of a L\u2010asparaginase\u2010based continuous chemotherapy protocol versus a short doxorubicin\u2010based induction chemotherapy protocol in dogs with malignant lymphoma","volume":"21","author":"Piek","year":"1999","journal-title":"Veterinary Quarterly"},{"key":"10.1016\/j.tvjl.2022.105854_bib26","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10545-016-9935-z","article-title":"Rapid quantification of underivatized amino acids in plasma by hydrophilic interaction liquid chromatography (HILIC) coupled with tandem mass-spectrometry","volume":"39","author":"Prinsen","year":"2016","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1016\/j.tvjl.2022.105854_bib27","first-page":"4554","article-title":"L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans","volume":"41","author":"Riccardi","year":"1981","journal-title":"Cancer Research"},{"key":"10.1016\/j.tvjl.2022.105854_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1008368916800","article-title":"L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving IM or IV Erwinia C. or E. coli L-asparaginase as first exposure","volume":"11","author":"Rizzari","year":"2000","journal-title":"Annals of Oncology"},{"issue":"Suppl. 1","key":"10.1016\/j.tvjl.2022.105854_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0b013e32835d7d85","article-title":"Optimizing asparaginase therapy for acute lymphoblastic leukemia","volume":"25","author":"Rizzari","year":"2013","journal-title":"Current Opinion in Oncology"},{"key":"10.1016\/j.tvjl.2022.105854_bib30","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2460\/javma.1989.194.11.1626","article-title":"L-asparaginase for treatment of lymphoid neoplasia in dogs","volume":"194","author":"Rogers","year":"1989","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"10.1016\/j.tvjl.2022.105854_bib31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2460\/ajvr.1991.53.04.580","article-title":"Effects of single-dose L-asparaginase on coagulation values in healthy dogs and dogs with lymphoma","volume":"53","author":"Rogers","year":"1992","journal-title":"American Journal of Veterinary Research"},{"key":"10.1016\/j.tvjl.2022.105854_bib32","first-page":"1009","article-title":"Asparaginase-associated pancreatitis in a dog","volume":"52","author":"Schleis","year":"2011","journal-title":"The Canadian Veterinary Journal"},{"key":"10.1016\/j.tvjl.2022.105854_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00685615","article-title":"L-asparaginase kills lymphoma cells by apoptosis","volume":"32","author":"Story","year":"1993","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.tvjl.2022.105854_bib34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0277-5379(90)90193-W","article-title":"Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma","volume":"26","author":"Teske","year":"1990","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.tvjl.2022.105854_bib35","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2460\/javma.1997.210.04.512","article-title":"Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995)","volume":"210","author":"Valerius","year":"1997","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"10.1016\/j.tvjl.2022.105854_bib36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2460\/javma.1999.214.03.353","article-title":"Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin","volume":"214","author":"Valerius","year":"1999","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"10.1016\/j.tvjl.2022.105854_bib37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.tvjl.2022.105854_bib38","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.2460\/ajvr.1986.47.06.1398","article-title":"Toxicologic studies of a conjugate of asparaginase and polyethylene glycol in mice, rats, and dogs","volume":"47","author":"Viau","year":"1986","journal-title":"American Journal of Veterinary Research"},{"key":"10.1016\/j.tvjl.2022.105854_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2141.2001.02680.x","article-title":"Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia","volume":"113","author":"Vieira Pinheiro","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.tvjl.2022.105854_bib40","first-page":"1731","article-title":"Anti-PEG IgE in anaphylaxis associated with polyethylene glycol","volume":"9","author":"Zhou","year":"2021","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023322000697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023322000697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:32:31Z","timestamp":1761071551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090023322000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":40,"alternative-id":["S1090023322000697"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2022.105854","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of PEG-L-asparaginase in asparagine suppression and anti-drug antibody development in healthy Beagle dogs: A multi-phase preclinical study","name":"articletitle","label":"Article Title"},{"value":"The Veterinary Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvjl.2022.105854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105854"}}